VEGFA and glioblastoma: Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody that has been thoroughly researched in recurrent glioblastoma, is one example of an antiangiogenic medication that has been reported to be an effective salvage treatment for progressive BSG in recent years [24].